Actym Therapeutics Appoints Chan Whiting as Chief Development Officer

BERKELEY, Calif., Nov. 11, 2021 -- (Healthcare Sales & Marketing Network) -- Actym Therapeutics, Inc. today announced the appointment of Chan Whiting, Ph.D. as Chief Development Officer. Chan brings over 20 years of drug development experience within the ... Biopharmaceuticals, Oncology, Personnel Actym Therapeutics, S. Typhimurium-Attenuated Cancer Therapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news